Evaluation of fecal microbiota, live (RBL) for the prevention of recurrent Clostridioides difficile infection: Canadian subgroup analysis of an open-label phase 3 study
Theodore Steiner, Thomas Louie, Dina Kao, Dan Smyth, Beth Guthmueller, Tracey Jason, Susan N Elliott, Shivam Srivastava, Christine Lee · 2026
Read Evaluation of fecal microbiota, live (RBL) for the prevention of recurrent Clostridioides difficile infection: Canadian subgroup analysis of an open-label phase 3 study by Theodore Steiner, Thomas Louie, Dina Kao, Dan Smyth, Beth Guthmueller, Tracey Jason, Susan N Elliott, Shivam Srivastava, Christine Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13639365.txt.
Description
Theodore Steiner and eight colleagues present a 2026 Canadian subgroup analysis of a fecal microbiota product for preventing repeat Clostridioides difficile infection. The live product, given rectally in a single dose after antibiotics, aims to restore gut microbes in adults whose infections keep returning.
Across five Canadian sites, 117 participants received the treatment. Side effects appeared in about six in ten people and were mostly mild gut complaints. Three quarters had treatment success at eight weeks, and most of those kept their response at six months. Results matched the wider trial, supporting use in Canada.
Catalog record
| CREATOR | Theodore Steiner, Thomas Louie, Dina Kao, Dan Smyth, Beth Guthmueller, Tracey Jason, Susan N Elliott, Shivam Srivastava, Christine Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23385 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |